for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Biotron Limited

BIT.AX

Latest Trade

0.11AUD

Change

0.00(0.00%)

Volume

3,535,402

Today's Range

0.10

 - 

0.11

52 Week Range

0.05

 - 

0.18

As of on the Australian Stock Exchange Ltd ∙ Minimum 15 minute delay

Pricing

Previous Close
0.11
Open
0.10
Volume
3,535,402
3M AVG Volume
78.21
Today's High
0.11
Today's Low
0.10
52 Week High
0.18
52 Week Low
0.05
Shares Out (MIL)
701.93
Market Cap (MIL)
73.70
Forward P/E
--
Dividend (Yield %)
--

Next Event

Biotron Ltd Annual Shareholders Meeting

Latest Developments

更多

Biotron Presenting New Data On Lead Hiv-1 Drug, BIT225

Biotron Ltd Says Gleneagle Will Underwrite Any Shortfall Arising From 103.1 Million Listed Options

Biotron Secures $4.7 Mln Underwriting Agreement With CPS Capital Group

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Biotron Limited

Biotron Limited is an Australia-based biotechnology company. The Company is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The Company is focused on the ongoing clinical development of its antiviral platform. The Company's lead antiviral drug, BIT225 is in mid-stage clinical development with approximately eight clinical trials completed. The Company has conducted clinical trails in human immunodeficiency virus-1 (HIV-1), hepatitis C virus (HCV) and HIV-1/HCV co-infected population. The clinical trials showed that BIT225 targets and reduces levels of HIV-1 residing in long-lived monocyte/macrophage reservoirs. BIT225 has clinical antiviral activity against both HIV-1 and HCV. BIT225 is pan-genotypic and is active against all HCV genotypes, including GT3. The Company designs and develops drugs that target a class of virus protein known as viroporins. Its earlier stage programs include Dengue, Influenza and others.

Industry

Biotechnology & Drugs

Contact Info

Suite 3.3, 56 Delhi Road

NORTH RYDE, NSW

2113

Australia

+61.2.98050488

http://www.biotron.com.au/

Executive Leadership

Michael John Hoy

Independent Non-Executive Chairman of the Board

Michelle Miller

Chief Executive Officer, Managing Director, Executive Director

Stephen L. Becker

Chief Medical Officer

Peter James Nightingale

Company Secretary

Stephen Alister Locarnini

Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
8.77
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.72
LT Debt To Equity (MRQ)
0.30
Return on Investment (TTM)
-45.11
Return on Equity (TTM)
-42.97

Latest News

Latest News

Bitstamp granted virtual currency license by New York financial regulator

Bitstamp, Europe's biggest digital asset exchange, has been granted a virtual currency license, the New York Department of Financial Services said on Tuesday.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up